R
Robert Tibshirani
Researcher at Stanford University
Publications - 620
Citations - 359457
Robert Tibshirani is an academic researcher from Stanford University. The author has contributed to research in topics: Lasso (statistics) & Gene expression profiling. The author has an hindex of 147, co-authored 593 publications receiving 326580 citations. Previous affiliations of Robert Tibshirani include University of Toronto & University of California.
Papers
More filters
Journal ArticleDOI
A component lasso
Nadine Hussami,Robert Tibshirani +1 more
TL;DR: It is proved that the component lasso is strongly sign consistent in a block‐diagonal setting and can outperform standard regression methods such as the lasso and elastic net, achieving a lower mean squared error as well as better support recovery.
Posted Content
Sensitivity Analysis for Inference with Partially Identifiable Covariance Matrices
TL;DR: In this article, a method based on semidefinite programming is proposed to automatically quantify the bias of missing value imputation via conditional expectation via conditional expectations, and the method can give an accurate assessment of the true error in cases where estimates based on sampling uncertainty alone are overly optimistic.
Journal ArticleDOI
FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421.
Norman J. Lacayo,Norman J. Lacayo,Soheil Meshinchi,Susana C. Raimondi,Dennis J. Kuo,Ron Yu,Myron Chang,C. L. Willman,Robert Tibshirani,Yaddanapudi Ravindranath,Branimir I. Sikic,Howard Weinstein,Gary V. Dahl,Gary V. Dahl +13 more
TL;DR: It is hypothesized that gene expression profiles would identify genes that cooperate with FLT3 mutations in conferring poor clinical outcome, and it is observed that patients with normal karyotypes who were enrolled in the Pediatric Oncology Group (POG) study #9421 had two significantly different clinical outcomes that were associated with the expression of FLT 3 mutations.
Journal ArticleDOI
Reply to D.R. Catchpoole et al
TL;DR: The development of truly personalized therapies will require ascertaining the key differences among individuals as well as similarities between cohorts within a disease type, which is a major challenge in clinical trials designs.